Efficacy and safety of treatment of moderate and severe psoriasis with the interleukin 23 inhibitor risankizumab
A review of the literature on the use of the genetically engineered biological drug Skyrizi (INN: risankizumab) for the treatment of psoriasis in patients is presented. The problem of high dissatisfaction of patients with the available means (methods) of therapy for this dermatosis is discussed. Inh...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Book |
| Published: |
State Scientific Center of Dermatovenereology and Cosmetology,
2022-09-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Internet
Connect to this object online.3rd Floor Main Library
| Call Number: |
A1234.567 |
|---|---|
| Copy 1 | Available |